Photobiomodulation for Dry Age Related Macula Degeneration
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with dry AMD in the study eye and wet AMD in the control eye
Exclusion Criteria:
- Geographic atrophy of the central macular region at enrolment
- Previous/ active wet AMD in the study eye
- A history of epilepsy
- Retinal diseases apart from AMD
- Significant media opacities
- Cataracts worse than grade 2 (LOCS III classification)
- Change in AREDS 2 supplements (vitamins) 1 month before the study and during the study trial was allowed.
- Ongoing systemic medications that are photosensitizing (e.g. tetracyclins)
- Systemic medications during the last 6 months that can cause deposits in the macular region (hydroxychloroquine, amiodarone)
- Unable to give informed consent
- Unable to cooperate with the treatment and follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
Near or infra red light provided by the Valeda machine will be applied in the intervention eye
|
Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
|
|
Sham Comparator: Control
Light with very low intensity provided by the same Valeda machine will be applied in the control eye
|
Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of patients that develope late AMD in the study eye compared with control after 3 years of follow-up
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 456056
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.